Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Ajanta Pharma Ltd.

31 Jan 2025

2576.85

1.52%

Ajanta Pharmaceuticals Q3 Results 2025 on 31 Jan, 2025: profit rise by 10.88% YOY, profit at 232.88 crore and revenue at 1146.13 crore

livemint

Ajanta Pharmaceuticals Q3 Results 2025 on 31 Jan, 2025: Revenue increased by 3.71% YoY & profit increased by 10.88% YoY, profit at 232.88 crore and revenue at 1146.13 crore.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore

Business Standard | 30 Jan 2025 1 more

Ajanta Pharma Ltd.

31 Jan 2025

2576.85

1.52%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

30 Jan 2025

2576.85

1.52%

to see Rapid results content

Ajanta Pharma Ltd.

30 Jan 2025

2576.85

1.52%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

11 Dec 2024

2576.85

1.52%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

11 Nov 2024

2576.85

1.52%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

05 Nov 2024

2576.85

1.52%

Ajanta Pharma share price zooms 4% as ex-dividend date looms; details here

Business Standard

The uptick comes ahead of the company's ex-dividend date tomorrow, driven by its recent dividend announcement that promises rewards for eligible shareholders

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

29 Oct 2024

2576.85

1.52%

Ajanta Pharma Q2 Results Review - Branded Generics Revenue Outperform Expectations: Systematix

NDTV Profit

New launches and an expected stable price erosion should contribute to a meaningful growth in top-line for the company supported by stable Ebitda margins, says the brokerage.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

28 Oct 2024

2576.85

1.52%

to see Rapid results content

Ajanta Pharma Ltd.

28 Oct 2024

2576.85

1.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year.